Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/1665
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOday Ezzat, Mohammed-
dc.contributor.authorAbd Razik, Basma-
dc.date.accessioned2022-10-16T05:23:28Z-
dc.date.available2022-10-16T05:23:28Z-
dc.date.issued2020-
dc.identifier.issn1307-2080-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/1665-
dc.description.abstractCelecoxib is one of the best potent nonsteroidal anti-inflammatory drug (NSAID) used as cyclooxygenase-2 (COX-2) selective inhibitor. For decades it effectively used in pain and inflammation treatment because the ability of reducing prostaglandin (PG) synthesis by obstruct the transformation of arachidonic acid to PGH2. But several serious side effects synchronized includes kidney failure, nausea, gastrointestinal tract bleeding, myocardial infarction, abdominal pain, and finally diarrhea. In this paper, a total of 155 Celecoxib derivatives were successfully docked inside crystal structure of cyclooxygenase-2 (COX-2) enzyme to estimate the potency of each derivative to bind inside active site. The highest twenty effective derivatives were recorded with docking score range of (-16.997 to -14.611) kcal/mol.en_US
dc.language.isoenen_US
dc.publisherActa Pharm. Sci.en_US
dc.subjectDrug Designen_US
dc.subjectDocking Studyen_US
dc.subjectScaffold hoppingen_US
dc.title"Molecular Drug Design and Docking Study of Novel N- substituted Celecoxib Derivatives as Selective Cyclooxygenase-2 Inhibitors"en_US
dc.typeArticleen_US
Appears in Collections:قسم الكيمياء

Files in This Item:
File Description SizeFormat 
pdf_677 - Dr. Mohammed Oday Ezzat.pdf436.58 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.